Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 14, 2014 - Issue 7
Submit an article Journal homepage
263
Views
14
CrossRef citations to date
0
Altmetric
Reviews

Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond

Niki KarachaliouInstituto Oncológico Dr Rosell, Quirón-Dexeus Hospital Universitario, Barcelona, Spain
,
Rafael RosellMedical Oncology Service, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain;Molecular Oncology Research (MORe) Foundation, Barcelona, SpainCorrespondence[email protected]
,
Daniela Morales-EspinosaInstitut d’Investigació Germans Trias i Pujol, Badalona, Barcelona, Spain
&
Santiago ViteriInstituto Oncológico Dr Rosell, Quirón-Dexeus Hospital Universitario, Barcelona, Spain
Pages 807-815 | Published online: 10 Mar 2014

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Niki Karachaliou, Manuel Fernandez Bruno, Jillian Wilhelmina Paulina Bracht & Rafael Rosell. (2019) Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives. OncoTargets and Therapy 12, pages 4567-4575.
Read now
Niki Karachaliou, Jordi Codony-Servat, Jillian Wilhelmina Paulina Bracht, Masaoki Ito, Martyna Filipska, Carlos Pedraz, Imane Chaib, Jordi Bertran-Alamillo, Andres Felipe Cardona, Miguel Angel Molina & Rafael Rosell. (2019) Characterising acquired resistance to erlotinib in non-small cell lung cancer patients. Expert Review of Respiratory Medicine 13:10, pages 1019-1028.
Read now
Niki Karachaliou, Mariacarmela Santarpia, Maria Gonzalez Cao, Cristina Teixido, Aaron E. Sosa, Jordi Berenguer, Alejandra Rodriguez Capote, Giuseppe Altavilla & Rafael Rosell. (2017) Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer. Expert Opinion on Investigational Drugs 26:6, pages 713-722.
Read now
Niki Karachaliou, Aaron E. Sosa, Feliciano Barron Barron, Maria Gonzalez Cao, Mariacarmela Santarpia & Rafael Rosell. (2017) Pharmacological management of relapsed/refractory NSCLC with chemical drugs. Expert Opinion on Pharmacotherapy 18:3, pages 295-304.
Read now
Niki Karachaliou & Rafael Rosell. (2014) Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics. Lung Cancer: Targets and Therapy 5, pages 73-79.
Read now

Articles from other publishers (9)

April L. Darling & Vladimir N. Uversky. 2023. Droplets of Life. Droplets of Life 271 335 .
Alexander Chi, Xia He, Lin Hou, Nam P. Nguyen, Guangying Zhu, Robert B. Cameron & Jay M. Lee. (2021) Classification of Non-Small Cell Lung Cancer’s Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint Blockade. Cancers 13:12, pages 2924.
Crossref
Dima A. Sabbah, Rima Hajjo & Kamal Sweidan. (2020) Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors. Current Topics in Medicinal Chemistry 20:10, pages 815-834.
Crossref
Kuan-Li Wu, Ying-Ming Tsai, Chi-Tun Lien, Po-Lin Kuo & and Jen-Yu Hung. (2019) The Roles of MicroRNA in Lung Cancer. International Journal of Molecular Sciences 20:7, pages 1611.
Crossref
Nannan Guo, Yingnan Zhao, Wen Zhang, Shaojun Li, Shanshan Li & Jianqi Yu. (2018) MicroRNA‑133a downregulated EGFR expression in human non‑small cell lung cancer cells via AKT/ERK signaling. Oncology Letters.
Crossref
Niki Karachaliou & Rafael Rosell. 2017. Encyclopedia of Cancer. Encyclopedia of Cancer 2579 2583 .
Chirag Shah, Timothy Smile, Naveen Karthik, Shireen Parsai, Kevin Stephans & Greg Videtic. (2016) Lung cancer radiation therapy: Defining optimal evidence-based treatment approaches. Applied Radiation Oncology, pages 4-11.
Crossref
Chia-Lin Liu, Su-Feng Chen, Min-Zu Wu, Shu-Wen Jao, Yaoh-Shiang Lin, Chin-Yuh Yang, Tsai-Yu Lee, Lian-Wu Wen, Guo-Lun Lan & Shin Nieh. (2016) The molecular and clinical verification of therapeutic resistance via the p38 MAPK-Hsp27 axis in lung cancer. Oncotarget 7:12, pages 14279-14290.
Crossref
Niki Karachaliou & Rafael Rosell. 2014. Encyclopedia of Cancer. Encyclopedia of Cancer 1 5 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.